Cumulative progress in nanoparticle development has opened a new era of targeted delivery of therapeutics to cancer cells and tissue. However, developing proper detection methods has lagged behind resulting in the lack of precise evaluation and monitoring of the systemically administered nanoparticles. RNA nanoparticles derived from the bacteriophage phi29 DNA packaging motor pRNA have emerged as a new generation of drugs for cancer therapy. Multifunctional RNA nanoparticles can be fabricated by bottom-up self-assembly of engineered RNA fragments harboring targeting (RNA aptamer or chemical ligand), therapeutic (siRNA, miRNA, ribozymes, and small molecule drugs), and imaging (fl uorophore, radiolabels) modules. We have recently demonstrated that RNA nanoparticles can reach and target intracranial brain tumors in mice upon systemic injection with little or no accumulation in adjacent healthy brain tissues or in major healthy internal organs. Herein, we describe various functional imaging methods (fl uorescence confocal microscopy, fl ow cytometry, fl uorescence whole body imaging, and magnetic resonance imaging) to evaluate and monitor RNA nanoparticle targeting to intracranial brain tumors in mice. Such imaging techniques will allow indepth evaluation of specifi cally delivered RNA therapeutics to brain tumors.
Introduction
For high-grade gliomas, conventional treatments involving surgical resection, radiation, and concurrent chemotherapy often result in poor survival and high recurrence [ 1 , 2 ] . A number of nanoparticlebased strategies mainly based on lipids, polymers, inorganic, and organic materials are being developed for targeting glioma [ 3 -9 ] . For effective glioma therapy, nanoparticles must be delivered systemically and specifi cally target intracranial tumors with minimal toxicity and side effects. Recently, RNA nanotechnology has emerged as a new generation platform for biological and medical applications [ 10 -12 ] . The packaging RNA (pRNA) of the bacteriophage phi29 DNA packaging motor is a highly versatile molecule [ 13 ] and can be used to construct varieties of RNA nanoparticles with precise control of shape, size, and stoichiometry [ 10 , 14 -21 ] . Various functional groups, such as imaging agents; targeting ligands; and therapeutic modules including siRNA, miRNA, or ribozymes can be easily integrated into the pRNA scaffold while retaining the three-dimensional folding and authentic functionalities of the incorporated functional modules [ 15 -18 ] . More practically, nontoxic and nonimmunogenic properties [ 21 ] coupled with favorable biodistribution and pharmacokinetic profi les [ 15 -18 , 21 , 22 ] make the RNA nanoparticles an attractive candidate for the development of cancer therapeutic agents. Recently, we demonstrated that RNA nanoparticles fabricated using the ultra-stable pRNA-3WJ motif as a scaffold [ 15 ] can target intracranial glioma tumors in mice with little or no collateral damage to healthy tissues [ 22 ] . Herein, various functional imaging techniques are described to detect and monitor the targeted delivery of RNA nanoparticles harboring imaging agents and therapeutic siRNAs to glioma-bearing mice. These functional detection methods will be benefi cial to researchers for developing multifunctional RNA nanoparticles for disrupting pathways involved in glioma pathogenesis.
Materials
All reagents should be analytical grade and RNase-and DNase-free to prevent RNA degradation. All the solutions should be prepared using Milli-Q water (18.2 MΩ•cm at 25 °C resistivity) treated with diethylprocarbonate (DEPC) and then autoclaved. All tubes and glassware used in preparation of buffers and reagents should be autoclaved. Gloves and lab coats should be worn at all times.
1. V1 grade MICA substrate, 25 mm × 75 mm ( Ted Pella ). 6. Pellet the precipitated RNA by centrifugation at 16,500 × g for 30 min ( see Note 8 ).
3-Aminopropyltriethoxysilane (APTES) ( Life Technologies
).
N,N -di-isopropylethylamine (DIPEA) ( Life Technologies

Equipment
7. Wash the RNA pellet with 70 % ethanol, and collect the RNA pellet by centrifugation at 16,500 × g for 30 min.
8. Dry the RNA pellet by using speed vacuum ( see Note 9 ).
9. Resuspend the dried RNA pellet in 0.05 % DEPC-treated water (or TMS or PBS buffer) and store at −20 °C until further use ( see Note 3 ).
10. Check RNA nanoparticle assembly from individual RNA fragments using 8-12 % native PAGE gels [ 15 -18 ] .
1. Assemble a mount that can hold the MICA sheets inside the desiccator ( see Note 10 ).
2. Cut two plastic caps from Eppendorf tubes and place at the bottom of the desiccator. 6. Close the lid and leave for ~2 h to functionalize.
7. Remove the reagents and purge the desiccator with Argon gas for 5 min.
8. Leave the mica sheets overnight to cure and store under Argon atmosphere.
1. Prepare a 20 ng/μL RNA solution in TMS buffer ( see Note 14 ).
2. Cut a ~1 × 1 cm piece of AP-MICA and glue to an AFM specimen support disk.
3. Place 5-10 μL of RNA solution on the MICA and incubate for 2-3 min. Tapping 6. Mount the sample on the AFM stage, load the tip, and align the photodiodes according to the manufacturer's instructions ( see Note 17 ).
AFM Imaging in
7. Tune the AFM probe to fi nd its resonance frequency and engage the surface ( see Note 18 ).
8. Slowly reduce the set-point voltage until the surface is visible, optimize the feedback gains and start imaging. 2. Feed the mice with folate-free diet ( Harlan ) at least for 2 weeks before an injection of folate-harboring RNA nanoparticles to reduce the serum level of free folate in mice blood stream.
3. Anesthetize the mouse by intraperitoneal injection of ketamine.
Brain Tumor Implantation in Mouse
Model System (Fig. 4 ) 1. Implant brain tumor as described in Subheading 3.5 .
2. At 15 days posttumor implantation, inject pRNA-3WJ nanoparticles dissolved in 100 μL of PBS through tail vein ( see Note 35 ).
3. Sacrifi ce the mouse at 15 h postinjection by cervical dislocation under anesthesia in CO 2 chamber.
4. Dissect out the brain in the dark place ( see Note 36 ).
Transfer the brain to IVIS Lumina Series III Pre-clinical In
Vivo Imaging System ( Perkin Elmer ) or comparable system.
6. Position the mouse brain on the stage inside the dark chamber.
7. Preset the focus on the brain by using bright fi eld CCD camera. (Fig. 4 ) 
Magnetic Resonance Imaging (MRI) for Location and Size of Implanted Brain Tumors in Mice
Ex vivo
Fluorescence Imaging on Brain TumorBearing Mice (Fig. 5 ) 8. Acquire fl uorescence imaging on the positioned brains with excitation at 640 nm and emission at 660 nm for 2 min exposure ( see Note 37 ). 1. Implant brain tumor in a mouse as described in Subheading 3.5 ( see Note 38 ).
2. Inject the brain tumor-bearing mice with RNA nanoparticles harboring siRNA against luciferase gene constituted in total volume of 100 μL of PBS through tail vein ( see Note 37 ).
3. Before/after the injection, subject the mouse to bioluminescence whole body imaging to detect endogenous luciferase expression level ( see Note 39 ).
4. Inject the mouse with 75 mg/kg Luciferin ( Perkin Elmer ) ( see Note 40 ).
5. Anesthetize the mouse in isofl urane-vapored chamber.
6. Position the anesthetized mouse on the stage inside the dark chamber. Keep the animal under anesthesia with low fl ow of isofl urane gas ( see Note 41 ). 
In vivo
. Bioluminescence intensity will correspond to the expression level of luciferase gene that a mouse bears.
Notes
1. Sterilize the PBS solutions by autoclaving at 121 °C for 20 min.
Cool down to and store at room temperature. Do not freeze or store in a refrigerator since phosphates will irreversibly precipitate.
2. Sterilize the TMS solution by autoclaving at 121 °C for 20 min.
3. Aliquot the RNA samples in small volumes and freeze them before use. Thaw the frozen RNA solution on ice. Avoid frequent freezing and thawing of RNA samples to preserve the quality of RNA samples.
Preformulated 4 % PFA solution is also available commercially.
Keep refrigerated for long-term storage.
Fig. 6
In vivo bioluminescence whole body imaging for detection of siRNA delivery into brain tumor. Gene silencing effect of pRNA-3WJ-Folate-siRNA(Luciferase) nanoparticles in human glioblatoma cell U87ΔEGFR-Luc derived mice brain tumors was evaluated by in vivo bioluminescence whole body imaging after systemic delivery. The change of luciferase activity from the brain tumors was compared to pRNA-3WJ-FolatesiRNA(Scramble) injected mice brains as negative controls. Pseudocolor was used to express the mean radiance (p/s/cm 5. Conventional gel imager is usually equipped with shortwavelength UV lamp, which is strong enough to cause chemical break on phosphodiester bonds on RNA strand. We recommend using a handheld UV lamp with long wavelength in a dark place.
6. The volume of elution buffer to be used can be determined by measuring the weight of gel piece. Use 1 mL of elution buffer for each gram of gel.
7. Alternatively, RNA can be precipitated at −80 °C for 20 min. However, overnight precipitation at −20 °C usually gives better results. If isopropyl alcohol is used instead of ethanol, use 1.5 × volume.
8. After centrifugation, the RNA may be visible as a white pellet if there is a high amount of RNA. However in many cases, the RNA pellet is not visible. To avoid disturbing the RNA pellet, be careful not to touch the area by a pipette tip when adding 70 % ethanol.
9. Be careful not to overdry the RNA pellet. Medium heat is recommended.
10. Anything that holds the MICA sheets safely above the surface is feasible, such as mounting the sheets on a rod with paper clips or fi xing them on top of a pipette tip box.
11. Use an overfl ow gauge to ensure pressure does not build up inside the desiccator due to the vacuum grease seal.
12. MICA sheets come in different thicknesses. Typically a MICA sheet can be cleaved multiple times to obtain 0.05-0.1 mm thickness. Label the outside surface to ensure only cleaved surfaces are used for sample preparation.
13. Fresh APTES should be used. If the surface shows heterogeneities after functionalization, the APTES has likely polymerized and needs to be vacuum distilled under Argon atmosphere. Store APTES under Argon.
14. The surface density varies with substrate functionalization, concentration, size, and shape of the samples. A total of 1-20 ng/μL are typical concentrations but might need to be optimized to ensure samples do not overlap.
15. The quality of the water plays an important role as Milli-Q or deionized water might still contain nanometer-sized particulates that will accumulate on the substrate and make imaging challenging.
16. The samples can be dried under an Argon stream or in the desiccator as well. Overnight is preferred as it also ensures that the epoxy support has fully cured.
17. The size of the RNA nanoparticles makes imaging challenging. Typically, ultrasharp tips are used as narrow as 1 nm with a spring constant of 40 N/m and a resonance frequency of >300 kHz.
18. Due to the fragility of ultrasharp Silicon tips, great care should be applied when approaching the surface and only low forces should be applied.
19. We recommend to plate 1 × 10 5 cells per well, which will reach 70-80 % of confl uence next day (about 24 h after the plating). Overplating of cells will reduce RNA binding and immunostaining effi ciency as well.
20. Folate-free culture media is recommended to ensure an effi cient recognition of folate receptors by folate ligand conjugated to RNA nanoparticles.
21. Trypsinization and neutralization can be carried out as general subculture method. Briefl y, incubate the cells in 0.05 % trypsin solution for no more than 5 min in CO 2 incubator followed by neutralizing with 10 × volume of culture media. Centrifuge to pellet the cells followed by washing the pellet with PBS, then centrifuge again . Remove the PBS. 27. Minimum volume to cover the surface area is 50 μL.
28. Alternatively, DAPI solution can be added to the mounting solution.
29. Leave the mounted chamber at room temperature for at least a half day to dry. Then, the chamber can be wrapped by aluminum foil and stored at 4 °C up to 1 month.
30. Acquire the fl uorescence from DAPI and Phalloidin Alexa 488 at minimum intensity to maximize that from Alexa 647 conjugated to RNA nanoparticles.
31. The injection can be carried out either by manually with a Hamilton syringe or an automatic injector by setting the injection speed at 0.4 μL per minute for total volume of 2 μL. 34. Tumor volume can be calculated from the outlined ROI.
35. Hold the mouse in a mouse restrainer to keep the mouse from wriggling while tail vein injection.
36. Keep the working place dark to minimize photobleaching of the fl uorophores in the tissue.
37. The acquisition time can be determined experimentally, since the optimal condition can vary depending on the strength of light source.
38. For an experiment of luminescence detection, human glioma cells transfected with luciferase gene can be used. After brain tumor implantation, we usually detect the luminescence at around 5 days as tumor grows.
39. Dissecting the brain out is not necessary. Unlike fl uorescence, bioluminescence can penetrate the mouse skull.
40. For the maximal luminescence intensity, the manufacturer recommends to inject up to 300 mg/kg of luciferin. However, 75 mg/kg usually produce enough strength of luminescence intensity from a mouse brain.
41. We usually reduce the fl ow rate of isofl urane gas at this step, since a high fl ow rate may kill the anesthetized mouse while imaging, which usually takes up to 10 min.
